Ascletis Pharma Inc.

Investors

2024

2023

2022

2021

2020

2019

2018

Grant of Share Options
2022-12-30
Voluntary Announcement - Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Inhibitor ASC10 and Its Derivatives
2022-12-19
Voluntary Announcement - Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
2022-12-12
Remuneration Committee - Terms of Reference
2022-12-08
Voluntary Announcement - Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
2022-12-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
2022-12-02
Voluntary Announcement - Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
2022-11-30
Voluntary Announcement - Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA
2022-11-29
Voluntary Announcement - Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
2022-11-23
Voluntary Announcement - Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
2022-11-17

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1